Literature DB >> 27398359

Hospital stays for hepatitis B or C virus infection or primary liver cancer among immigrants: a census-linked population-based cohort study.

Edward Ng1, Robert P Myers1, Doug Manuel1, Claudia Sanmartin1.   

Abstract

BACKGROUND: The recent increase in the incidence of primary liver cancer in Canada has been attributed to a higher proportion of immigrants from countries endemic for hepatitis B virus (HBV) and hepatitis C virus (HCV). We examined hospital discharges for liver disease in Canada, focusing on those for all liver-related diseases, HBV infection, HCV infection and primary liver cancer, by 3 immigration-related variables: immigration status, duration of residence in Canada and risk level of the source country.
METHODS: We calculated annualized crude and age-standardized rates of a hospital stay in Canada for HBV infection, HCV infection, primary liver cancer and all liver-related diseases using data from the 2006 Canadian census (long form) linked to the Canadian Institute for Health Information Discharge Abstract Database for fiscal years 2006/07 to 2008/09. We estimated the odds of a hospital stay using logistic regression for the 3 immigration-related variables, adjusting for sociodemographic indicators.
RESULTS: Immigrants were less likely than Canadian-born residents to be discharged with a diagnosis of any liver-related condition (odds ratio [OR] 0.83, 95% confidence interval [CI] 0.78-0.89); however, they were more likely to be discharged with a diagnosis of HBV infection (OR 2.02, 95% CI 1.57-2.60) and primary liver cancer (OR 1.43, 95% CI 1.22-1.68). There was a clear association between a hospital stay for HBV infection and immigration from HBV-endemic countries (OR 5.15, 95% CI 3.87-6.84) and between a stay for HCV infection and immigration from HCV-endemic countries (OR 2.98, 95% CI 1.74-5.11). Adjustment for low income status and urban residence did not change the results.
INTERPRETATION: Although the odds of a liver-related hospital stay were lower among immigrants than among those born in Canada, immigrants from countries at high risk for HBV infection, HCV infection and primary liver cancer were more likely than Canadian-born residents to have a corresponding liver-related hospital stay. These findings emphasize the importance of identifying immigrants with hepatitis and engaging them in care to prevent complications.

Entities:  

Year:  2016        PMID: 27398359      PMCID: PMC4933632          DOI: 10.9778/cmajo.20150117

Source DB:  PubMed          Journal:  CMAJ Open        ISSN: 2291-0026


  21 in total

1.  Global hepatitis, migration and its impact on Western healthcare.

Authors:  Furqaan Ahmed; Graham R Foster
Journal:  Gut       Date:  2010-08       Impact factor: 23.059

2.  Two approaches to linking census and hospital data.

Authors:  Michelle Rotermann; Claudia Sanmartin; Gisèle Carrière; Richard Trudeau; Hélène St-Jean; Abdelnasser Saïdi; Alexander Reicker; Aimé Ntwari; Eric Hortop
Journal:  Health Rep       Date:  2014-10       Impact factor: 4.796

3.  A Canadian screening program for hepatitis C: is now the time?

Authors:  Hemant A Shah; Jenny Heathcote; Jordan J Feld
Journal:  CMAJ       Date:  2013-09-30       Impact factor: 8.262

4.  Disparities in mortality patterns among Canadian immigrants and refugees, 1980-1998: results of a national cohort study.

Authors:  Marie DesMeules; Jenny Gold; Sarah McDermott; Zhenyuan Cao; Jennifer Payne; Bryan Lafrance; Bilkis Vissandjée; Erich Kliewer; Yang Mao
Journal:  J Immigr Health       Date:  2005-10

5.  A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

Authors:  Susan T Goldstein; Fangjun Zhou; Stephen C Hadler; Beth P Bell; Eric E Mast; Harold S Margolis
Journal:  Int J Epidemiol       Date:  2005-10-25       Impact factor: 7.196

6.  Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.

Authors:  Yen-Tsung Huang; Chin-Lan Jen; Hwai-I Yang; Mei-Hsuan Lee; Jun Su; Sheng-Nan Lu; Uchenna H Iloeje; Chien-Jen Chen
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

7.  Cancer incidence among Canadian immigrants, 1980-1998: results from a national cohort study.

Authors:  Sarah McDermott; Marie Desmeules; Roxanne Lewis; Jenny Gold; Jennifer Payne; Bryan Lafrance; Bilkis Vissandjée; Erich Kliewer; Yang Mao
Journal:  J Immigr Minor Health       Date:  2011-02

8.  Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam, The Netherlands.

Authors:  Irene K Veldhuijzen; Reinoud Wolter; Vincent Rijckborst; Marijke Mostert; Helene A Voeten; Yiu Cheung; Charles A Boucher; Jurriën G P Reijnders; Onno de Zwart; Harry L A Janssen
Journal:  J Hepatol       Date:  2012-08-08       Impact factor: 25.083

9.  The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004.

Authors:  Robert P Myers; MingFu Liu; Abdel Aziz Shaheen
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

Review 10.  Burden of disease and cost of chronic hepatitis C infection in Canada.

Authors:  Robert P Myers; Mel Krajden; Marc Bilodeau; Kelly Kaita; Paul Marotta; Kevork Peltekian; Alnoor Ramji; Chris Estes; Homie Razavi; Morris Sherman
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05
View more
  2 in total

Review 1.  Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada.

Authors:  Christina Greenaway; Iuliia Makarenko; Fozia Tanveer; Naveed Z Janjua
Journal:  Can Liver J       Date:  2018-07-17

2.  Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada.

Authors:  Mawuena Binka; Zahid A Butt; Stanley Wong; Mei Chong; Jane A Buxton; Nuria Chapinal; Amanda Yu; Maria Alvarez; Maryam Darvishian; Jason Wong; Gina McGowan; Mikhail Torban; Mark Gilbert; Mark Tyndall; Mel Krajden; Naveed Z Janjua
Journal:  World J Gastroenterol       Date:  2018-03-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.